588 related articles for article (PubMed ID: 8884115)
1. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
2. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
[TBL] [Abstract][Full Text] [Related]
3. Immunologic monitoring with Orthoclone OKT3 therapy.
Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
[TBL] [Abstract][Full Text] [Related]
5. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
Cantarovich M; Latter DA; Loertscher R
Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
[TBL] [Abstract][Full Text] [Related]
6. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation.
Meiser BM; Uberfuhr P; Fuchs A; Schulze C; Nollert G; Mair H; Martin S; Pfeiffer M; Reichenspurner H; Kreuzer E; Reichart B
J Heart Lung Transplant; 1997 Aug; 16(8):795-800. PubMed ID: 9286771
[TBL] [Abstract][Full Text] [Related]
9. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
10. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
[TBL] [Abstract][Full Text] [Related]
11. Two low-dose OKT3 induction regimens following renal transplantation--clinical experience at a single center.
Oh HK; Provenzano R; Tayeb J; Satmary N; Jones B
Clin Transplant; 1998 Aug; 12(4):343-7. PubMed ID: 9686329
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
[TBL] [Abstract][Full Text] [Related]
13. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.
Woodle ES; First MR; Pirsch J; Shihab F; Gaber AO; Van Veldhuisen P;
Ann Surg; 2008 Oct; 248(4):564-77. PubMed ID: 18936569
[TBL] [Abstract][Full Text] [Related]
14. OKT3 treatment of cardiac allograft rejection.
Haverty TP; Sanders M; Sheahan M
J Heart Lung Transplant; 1993; 12(4):591-8. PubMed ID: 8369321
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
Macris MP; Frazier OH; Lammermeier D; Radovancevic B; Duncan JM
J Heart Transplant; 1989; 8(4):281-7. PubMed ID: 2504894
[TBL] [Abstract][Full Text] [Related]
16. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
[TBL] [Abstract][Full Text] [Related]
17. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
Guttmann RD; Flemming C
Clin Transplant; 1997 Jun; 11(3):185-92. PubMed ID: 9193840
[TBL] [Abstract][Full Text] [Related]
18. The duration of administration of monoclonal antibody OKT3 for induction immunosuppression after heart transplantation.
Aleksic I; Freimark D; Blanche C; Czer LS; Dalichau H; Valenza M; Takkenberg JJ; Trento A
Thorac Cardiovasc Surg; 1997 Aug; 45(4):190-5. PubMed ID: 9323821
[TBL] [Abstract][Full Text] [Related]
19. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients.
Toyoda M; Galfayan K; Wachs K; Czer L; Jordan SC
Clin Transplant; 1995 Dec; 9(6):472-80. PubMed ID: 8645891
[TBL] [Abstract][Full Text] [Related]
20. The reuse of OKT3 after previous rejection or induction therapy in cadaveric renal transplantation.
Shield CF; Hughes JD
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):35-8. PubMed ID: 2510509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
